What are the best healthcare market research companies in Brazil?
The leading healthcare market research companies in Brazil are BioNixus (full-service global firm with ANVISA-aware pharma and FMCG research), IQVIA Brazil (pharma sales data and real-world evidence), Kantar Brazil health practice (OTC brand tracking and patient surveys), NielsenIQ Brazil (pharmacy channel measurement), and Euromonitor International (consumer health syndicated intelligence). For comprehensive pharmaceutical research including primary studies, KOL mapping, and HEOR, BioNixus offers the broadest scope.
What are the best healthcare market research agencies in Brazil?
Healthcare market research agencies in Brazil are the same buyer shortlist as companies: BioNixus for ANVISA-aware primary HCP, KOL, and CONITEC/HEOR research; IQVIA for prescription audits and RWE; Kantar for consumer health; NielsenIQ for OTC retail; and Euromonitor for syndicated sizing. Choose a primary-research agency for custom fieldwork; choose a data platform for audits and syndicated reports.
What is ANVISA and how does it affect pharmaceutical market research in Brazil?
ANVISA (Agencia Nacional de Vigilancia Sanitaria) is Brazil's national health surveillance agency responsible for regulating pharmaceutical products, clinical studies, health claims, and market authorization. ANVISA requirements shape how research is designed for regulatory submissions, how health claims are tested, and how market access strategies are developed. Research firms with ANVISA regulatory knowledge design studies that generate evidence usable in both commercial and regulatory contexts.
What is CONITEC and why does it matter for healthcare research in Brazil?
CONITEC (Comissao Nacional de Incorporacao de Tecnologias no SUS) is Brazil's health technology assessment body that recommends which pharmaceuticals and technologies should be included in the SUS (public health system) formulary. CONITEC assessments require robust HEOR evidence including cost-effectiveness data, budget impact models, and comparative effectiveness studies. Healthcare research firms that understand CONITEC submission requirements help pharma companies build the evidence packages needed for SUS formulary inclusion.
What is the SUS and how does it affect pharmaceutical market access research?
SUS (Sistema Unico de Saude) is Brazil's universal public health system covering approximately 75% of the population. For pharmaceutical companies, SUS formulary inclusion (via CONITEC) can dramatically impact commercial success. Research targeting the SUS market requires understanding federal, state, and municipal formulary structures, government procurement processes, and the payer decision-making hierarchy. Private market research (covering ANS-regulated health plans) requires separate methodologies and data sources.
Which research firms cover both FMCG and healthcare in Brazil?
BioNixus is uniquely positioned as a global insights firm covering both FMCG/consumer and healthcare/pharmaceutical research in Brazil. This dual capability is particularly valuable for companies managing brands at the prescription/OTC interface, or multinationals with both food/beverage and healthcare portfolios who prefer a single research partner with global methodology standards.
What research methods are used for pharmaceutical studies in Brazil?
Healthcare market research in Brazil uses KOL identification and mapping studies, HCP (physician, pharmacist, nurse) surveys via online panels or in-person interviews, patient surveys and PRO (patient-reported outcome) studies, prescription audit data analytics, HEOR (health economics and outcomes research), payer interviews with CONITEC/SUS decision-makers, and ethnographic patient journey research. ANVISA requirements may influence research design for studies feeding regulatory submissions.
How should I choose a healthcare market research partner for Brazil?
Key selection criteria for healthcare market research in Brazil include: ANVISA regulatory knowledge for submission-ready research design, CONITEC/HTA expertise for SUS market access, KOL mapping capabilities across specialties, HCP panel quality (physician, pharmacist, nurse coverage), HEOR and health economics capabilities, SUS vs. private payer research expertise, and the ability to combine healthcare insights with broader consumer and FMCG research for companies with diverse portfolios.
Does BioNixus conduct healthcare research in Brazil?
Yes. BioNixus is a global market research and insights firm that conducts primary pharmaceutical and healthcare research in Brazil including ANVISA-aware study design, CONITEC-informed HEOR evidence, KOL mapping across therapy areas, HCP surveys, market access intelligence, and SUS/private payer segmentation. BioNixus combines these healthcare capabilities with FMCG and consumer research for clients with diversified portfolios in Brazil.
Can Brazil healthcare research connect to USA and Europe programmes?
Yes. BioNixus designs Brazil healthcare research to connect to global benchmarking — allowing pharmaceutical and biotech clients to compare Brazilian HCP attitudes, payer dynamics, and market access conditions against the USA, Europe, Canada, and MENA using consistent survey instruments. Brazil-specific adaptations (ANVISA, CONITEC, SUS vs private) are layered within globally consistent methodologies.